851 – Pharmacokinetics of a Novel Dose Ratio of DTG/FTC/TAF for African Children With HIV (UNIVERSAL1)
Background To accelerate development of pediatric antiretroviral formulations for children, the WHO-led Paediatric Antiretroviral Drug Optimization group regularly reviews priorities for drug development. High on this priority list is a dispersible fixed dose combination of dolutegravir (DTG), emtricitabine (FTC) and tenofovir alafenamide fumarate (TAF) for treatment of ART naïve and experienced children living with HIV. The optimal dose ratio for this novel DTG/FTC/TAF pediatric tablet is 5/15/1.88 mg…